The FDA has cleared Keytruda in combination with chemotherapy – with or without bevacizumab – for patients with persistent, recurrent or metastatic cervical cancer whose tumours express PD-L1.
In the Phase III KEYNOTE-826 trial in this patient population, Keytruda plus chemotherapy – with or without bevacizumab – demonstrated both superior overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in PD-L1-positive patients.
On top of that, more patients responded to Keytruda plus chemotherapy compared to chemotherapy alone, with an objective response rate (ORR) of 68% versus 50%.
